Real-World Effectiveness, Safety, and Health-Related Quality of Life in Patients Receiving Adjuvant Nivolumab for Melanoma in Belgium and Luxembourg: Results of PRESERV MEL

Real-World Effectiveness, Safety, and Health-Related Quality of Life in Patients Receiving Adjuvant Nivolumab for Melanoma in Belgium and Luxembourg: Results of PRESERV MEL

Background: Nivolumab, an anti–programmed cell death 1 immuno-oncology therapy, is approved as an adjuvant treatment for patients with completely resected stage III or stage IV melanoma. PRESERV MEL (Prospective and REtrospective Study of nivolumab thERapy in adjuVant MELanoma) is a real-world obser...

Full description

Bibliographic Details
Main Authors: Anne Rogiers, Laurence Willemot, Laura McDonald, Hilde Van Campenhout, Guy Berchem, Celine Jacobs, Nathalie Blockx, Andrée Rorive, Bart Neyns
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:Cancers
Subjects:
adjuvant treatment
effectiveness
health-related quality of life
melanoma
nivolumab
real-world
Online Access:https://www.mdpi.com/2072-6694/15/19/4823

Internet

https://www.mdpi.com/2072-6694/15/19/4823

Similar Items